Jun 10, 2016 Syros Pharmaceuticals Presents Data Demonstrating Significant Anti-Tumor Activity of its Lead Drug Candidates at 21st Congress of the European Hematology Association
May 31, 2016 Syros Pharmaceuticals Announces FDA Acceptance of IND to Advance SY-1425 Into Phase 2 Clinical Trial
May 19, 2016 Syros Pharmaceuticals to Present on its Two Lead Programs, SY-1425 and SY-1365, at 21st Congress of the European Hematology Association
Apr 20, 2016 Syros Pharmaceuticals Presents New Data Demonstrating Significant Anti-Tumor Activity of its Selective CDK7 Inhibitor in Preclinical Models of Acute Myeloid Leukemia
Apr 18, 2016 Syros Pharmaceuticals Presents Data Demonstrating Significant Anti-Cancer Activity of SY-1425 in Preclinical Models of Acute Myeloid Leukemia
Mar 16, 2016 Syros Pharmaceuticals to Present Preclinical Data on SY-1425 and CDK7 Inhibitor Program in Blood Cancers at Upcoming AACR Annual Meeting
Mar 3, 2016 Publication in Science Further Validates Importance of Gene Control Research in Yielding New Insights into Diagnosing and Treating Cancer
